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Hepatitis E virus (HEV) causes several outbreaks of hepatitis in humans. 
Many aspects of HEV pathogenesis are not well understood. The HEV ORF3 product 
(henceforth known as vp13) is a multifunctional protein essential for infection of 
animals. To better understand the vp13 functions, this study was performed. We 
observed that vp13 protein was associated with the microtubules (MT) in transfected 
cells. Mutational studies revealed that both hydrophobic domains at the N-terminal 
region of vp13 are required for the vp13-MT interaction. Our studies also showed that 
HEV vp13 protein increased the stability of the MT, activated the apoptotic pathway, 
and, increased the levels of tumor suppressor gene p53 and its downstream effector 
p21Cip/WAF1 in the transfected cells. However, no noticeable effect on cell survival was 
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Chapter 1: General Background 
 
Hepatitis E virus (HEV) is a single-stranded positive-sense RNA virus that is 
classified as the sole member of the genus Hepevirus (Emerson et al., 2004; Emerson & 
Purcell, 2003). HEV is the causative agent of hepatitis outbreaks in developing countries 
and sporadic cases of acute hepatitis in developed countries (Emerson et al., 2004; 
Emerson & Purcell, 2003). It is transmitted by feco-oral route, mainly through 
contaminated water, although perinatal and parenteral routes have been documented. 
HEV infection is more common among young adults and the mortality rate ranges from 
0.5 to 3%. A fulminant form of hepatitis E that occurs in pregnant women, especially in 
their third trimester of gestation, is a striking feature of HEV infection and can lead to up 
to 20% mortality rate for the infected woman. (Purcell & Emerson, 2001).  
 
There are four major genotypes of HEV strains and a single known serotype. 
HEV is a zoonotic agent and animal HEV strains in swine and chicken are found in the 
U.S. (Haqshenas et al., 2001; Meng et al., 1997). Swine HEV was isolated in US, Japan 
and many other countries and their sequences were identified to be similar to locally-
characterized human HEV isolates. HEV was also isolated from wild deer and 
undercooked deer meat (Li et al., 2005; Tei et al., 2003). These data show that HEV is 
indeed a zoonotic virus and domestic swine, wild deer and boars are potential reservoirs 
of HEV in nature (Goens & Perdue, 2004). Other species with reported susceptibility to 
HEV infection include sheep (Usmanov et al., 1994), rat (Maneerat et al., 1996) and 





The genome of HEV is about 7.2 kb in length and consists of three open reading 
frames (ORF) (Tam et al., 1991). ORF1 encodes a nonstructural polyprotein that includes 
the RNA-dependent RNA polymerase. ORF2 encodes the capsid protein – a major 
structural protein in the virion. ORF3 encodes a phosphoprotein that was found to be 
essential for experimental HEV infection in macaques and pigs (Graff et al., 2005; Huang 
et al., 2007). The exact functions of vp13 in HEV infection remain unknown though a 
number of studies have found that it may play a role in cellular signaling pathways (Kar-
Roy et al., 2004; Korkaya et al., 2001; Moin et al., 2007; Tyagi et al., 2002; Tyagi et al., 
2005; Tyagi et al., 2004; Zafrullah et al., 1997).  
 
Attempts to gain more insights into HEV infection, pathogenesis or basic viral 
replication mechanisms have been hindered by several reasons that include lack of an 
effective in vitro cell culture system and a suitable animal model. Therefore, propagation 
of HEV and studies of virus replication still rely upon non-human primates or cells 
transfected with cloned replicons of HEV (Emerson et al., 2001; Panda et al., 2000). To 
specifically study the function of individual HEV proteins, scientists rely on 
overexpression of these proteins in mammalian cells transiently or stably. Due to lack of 
efficient cell culture for HEV propagation, functional study of ORF3 in HEV biology and 
infection has been limited, and therefore, the function of the protein is not yet clearly 
defined. Hence, this study was performed in an attempt to gain insights into the roles of 




In the following sections, literature on HEV is reviewed, background for this 





Chapter 2: Literature Review 
 
Hepatitis, or inflammation of the liver, is a serious illness that often leads to very 
high mortality in human beings. There are several etiologies for hepatitis among which 
infectious agents play a significant role. Several bacteria and viruses directly or indirectly 
lead to liver damage. Common etiological agents of viral hepatitis include: Hepatitis A 
virus (Picornaviridae), Hepatitis B virus (Hepadnaviridae), Hepatitis C virus 
(Flaviviridae), Hepatitis D virus (unclassified agent) and Hepatitis E virus (Hepeviridae). 
  
2.1 Introduction on Hepatitis E 
Hepatitis E is now recognized as an important public health problem in 
developing countries. It has been reported that, an estimated one-third of world’s 
population has been infected with Hepatitis E virus on the basis of seroprevalence. It has 
been a common cause of major epidemics of water-borne hepatitis in Southeast Asia for 
at least 50 years. The disease was previously referred as enterically transmitted non-A, 
non-B hepatitis. Hepatitis E is caused by infection with HEV, a non-enveloped, single-
stranded, positive-sense RNA virus. Hepatitis E virus is transmitted primarily via the 
fecal-oral route (Panda et al., 2007). Other documented routes of transmission include 
parenteral transmission, zoonotic food-borne transmission and vertical transmission. 
Several reports have suggested the possibility of a parenteral mode of 
infection/transmission for HEV (Chauhan et al., 1993). Hepatitis E is primarily a water-
borne disease, and contaminated water and food supplies have been implicated in major 




 HEV causes acute and sporadic viral epidemics but usually rare chronic 
infections. Clinical cases occur predominantly in developing countries in Asia, Africa, 
and Mexico (Purcell & Emerson, 2001). Recently, hepatitis E has also been recognized 
frequently in industrialized countries where it was not thought to be endemic. The 
existence of autochthonous hepatitis E in developed countries like France, Germany and 
England indicates that hepatitis E is no longer an imported disease (Buisson & Nicand, 
2006; Dalton et al., 2007; Preiss et al., 2006). Onset of symptoms usually occurs about 28 
to 36 days post-infection (Balayan et al., 1983). Typical signs and symptoms of hepatitis 
E include jaundice, malaise, anorexia, abdominal pain, vomiting and hepatomegaly.  It is 
usually an acute self-limiting disease, running a course of few weeks. In uncomplicated 
cases, recovery usually takes place within a month. Recently, more cases of persistent 
HEV infection with chronic hepatitis and cirrhosis are reported in patients with reduced 
immune surveillance as induced by chemotherapy or post-transplant immune suppression 
(Khuroo & Khuroo, 2008). 
 
HEV causes an unusually fulminant form of hepatitis in pregnant women, especially in 
their third trimesters of pregnancies (Khuroo et al., 2004). Mortality rate in these cases 
are approximately 20%. HEV-induced damage to Kupffer cells in the liver may allow for 
damage to the liver from endotoxins produced by intestinal gram-negative bacteria, 
which is referred as a kind of Schwartzman-like phenomenon and has been postulated as 
a possible reason for the high incidence of fulminant hepatitis in pregnant women (Goens 
& Perdue, 2004) . It has also been reported that 30-100% of fetuses or infants acquire the 




al., 2003). HEV is also responsible for sporadic fulminant hepatitis in adults and children 
(Nanda et al., 1994). 
 
2.2 Biology of Hepatitis E Virus 
The unavailability of a suitable culture system for laboratory propagation of HEV 
has largely hampered better understanding of HEV biology. Conventional cell culture 
techniques to cultivate this virus have so far not been successful. However, some 
continuous cell lines such as A549, 2BS, HepG2, KMB17 and BEL7402 have been 
useful to some extent since they are reported to be slightly susceptible to HEV (Huang et 
al., 1992; Le et al., 2001; Li et al., 1995), but hardly used or repeated elsewhere due to 
their extremely low efficiency or other unknown reasons. A549, human lung carcinoma 
cell line has been used on numerous occasions to isolate and cultivate HEV by some 
investigators (Huang et al., 1995; Huang et al., 1992; Le et al., 2001; Wei et al., 2000). 
Recently, a group from Japan reported the propagation of HEV in hepatocarcinoma cell 
line (PLC/PRF/5) with a very long cultivation time over two months  (Takahashi et al., 
2008). Many cell lines, including Vero and HeLa cells, do not seem to be sensitive to 
HEV replication (Le et al., 2001). Several research groups are actively searching for a 
suitable cell culture system for in vitro propagation of HEV. An alternative approach has 
been widely pursued by several research groups around the world by using HEV 
replicons or RNA transcripts. In 2004, Emerson et al reported the detection of viral 
antigen and the recovery of infectious virus from transfected PLC/PRF/5 and Huh-7 cells. 
These findings show that HEV can replicate in a limited number of cell lines of hepatic 




difficult virus to study in vitro (Purcell & Emerson, 2001). The replicon approach has 
been helpful in studying basic mechanisms of HEV replication and other biological 
characteristics.  
 
Several species of non-human primates have been utilized in studies involving 
disease reproduction and transmission and also for amplification of HEV. Experimental 
infections have been carried out in non-human subjects like chimpanzees, cynomolgus 
macaques, rhesus macaques, pig tail monkeys, African green monkeys, tamarins, owl 
monkeys and squirrel monkeys (Ray et al., 1991; Tsarev et al., 1993). The most useful 
subjects are cynomolgus and rhesus monkeys. Other animals such as pigs (Balayan et al., 
1990; Usmanov et al., 1991), rats (Maneerat et al., 1996)  and chickens (Haqshenas et al., 
2002; Huang et al., 2002a) have also been reported to be susceptible to HEV infections. 
Though the animals experimentally infected with HEV usually show biochemical and 
histological evidence of hepatitis, surprisingly, they do not develop clinical disease and 
therefore do not mimic human infections (Longer et al., 1993).  
 
Extensive sequence divergence is found among HEV strains isolated around the 
world. Phylogenetic analyses have classified HEV isolates into four major genotypes. 
Genotype 1 (Asia, North Africa) was initially thought to infect only humans, but a report 
from Cambodia showed that it was also detected from a pig (Zhang et al., 2008). 
Genotype 2 is prevalent in Mexico and Southern Africa. Genotype 3 (North and South 
America, Europe, Asia) is prevalent in swine herds and humans all over the world, and 




(Schlauder & Mushahwar, 2001). Cross protection between HEV genotype 1 and 4 has 
been demonstrated in rhesus macaques (Huang et al., 2008). 
 
           It is believed that an environmental reservoir of HEV exists, especially in the 
endemic areas, resulting in recurrent epidemic episodes. However, HEV is thermally 
much less stable than hepatitis A virus (Emerson et al., 2005). HEV is very fragile under 
conditions of high salt concentrations, freeze thawing and pelleting (Bradley et al., 1992). 
Individuals who have sporadic or sub-acute/sub-clinical hepatitis E could also be a 
potential reservoir for HEV. Numerous studies have indicated the presence of HEV in 
feces of swine, and identified HEV antibodies in sera of pigs (Clayson et al., 1995; Meng 
et al., 1998b; Meng et al., 1997), cattle (Favorov et al., 2000), sheep (Favorov et al., 
2000), goats (Favorov et al., 2000), horses (Saad et al., 2007), and rodents (He et al., 
2002; Kabrane-Lazizi et al., 1999a; Karetnyi Iu et al., 1993), further suggesting the 
possibility of several animal reservoirs. The isolation of Swine HEV (Meng et al., 1997) 
and Avian HEV (Haqshenas et al., 2001) further confirms the existence of animal 
reservoirs. Swine isolate and US strain of human HEV shows 99% sequence identity 
(Meng et al., 1997). HEV isolates of genotype 3 are grouped into three phylogenetic 
clusters, with the highest nucleotide identity being 94.4-100% between human and swine 
isolates in each cluster (Takahashi et al., 2003).  Experimental evidence of cross-species 
infection between human and swine HEV isolates have been reported (Meng, 2003). 
Avian HEV shows 50% sequence identity to human HEV and is considered to be placed 





HEV belongs to the family Hepeviridae, genus hepevirus. It shares some 
similarity in virion size and structure with members of the family Caliciviridae and hence 
was initially classified under that family (Miller, 1995). However, HEV was later 
removed from this family since its genome organization was found to be very different 
from that of the members of the Calicivirus family. Based on the presence of homologous 
regions present across the genome and the production of subgenomic RNA during 
replication, HEV was once thought to be a non-enveloped alpha-like virus (Purdy et al., 
1993). Phylogenetic analysis of the RNA helicase and RNA-dependent RNA polymerase 
(RdRp) regions of HEV denoted that HEV formed a distinct group, closer to rubella virus 
(family Togaviridae) than to the members of Caliciviridae (Koonin et al., 1992). Finally, 
the virus was assigned into a separate family Hepeviridae (Emerson et al., 2004). 
 
Due to lack of efficient cell culture system and a useful animal model, the HEV 
replication mechanism was proposed on the basis of similarities and sequence homology 
to other better characterized positive-sense RNA viruses (Reyes et al., 1993). The 
genomic RNA in HEV replicates through a negative-strand RNA intermediate. The 
presence of both positive and negative-strand HEV RNA are identified in the liver of 
rhesus monkeys experimentally infected, while only positive strand RNA was found in 
the serum and bile, where only mature virions are expected in an experimental study 
using rhesus monkeys (Nanda et al., 1994). In another study using swine animal model, 
replicative negative-strand HEV RNA was detected in the small intestines, lymph nodes, 
colons, and livers  indicating the possibility of HEV replication in tissues other than  liver 




been shown to be essential. (Kabrane-Lazizi et al., 1999b). It has been demonstrated by 
RNA-protein interaction study, the specific binding of purified and refolded recombinant 
HEV RdRp protein to the 3′ end of its RNA genome containing the poly(A) stretch 
(Agrawal et al., 2001). Though several reports have attempted to elucidate the replication 




2.3 Molecular Virology 
HEV genome is a positive-sense, single-stranded RNA genome that is 
approximately 7 kb long (Fig. 1). It is a non-enveloped virus that has a diameter of 27-34 
nm. The virus particles were first visualized in stool samples using immune electron 
microscopy (Balayan et al., 1983). Virus preparations from stool samples revealed a 
virion density of 1.29 g/ml in potassium tartarate and glycerol gradient (Bradley et al., 
1992). 
 
The first full-length genome sequence of HEV was determined in 1991 for a 
strain from Burma (Tam et al., 1991). HEV genome is 7.2 kb in size with three open 
reading frames (Aye et al., 1992; Kabrane-Lazizi et al., 1999b; Purdy et al., 1993; Tam et 
al., 1991; Yin et al., 1994). At the 5  terminus of the genome is a 28-nucleotide (nt) long 
small untranslated region (UTR) which forms a hairpin structure (Huang et al., 1992). 
The genomic RNA of HEV also possesses a methylated cap at its 5  terminus (Kabrane-




nt long UTR precedes the poly A tail (Tam et al., 1991). These 5  and 3  cis acting 
elements are believed to play important roles in viral replication and transcription 
(Agrawal et al., 2001; Purdy et al., 1993). In infected liver cells of an experimentally 
infected monkey, two subgenomic viral RNA of 3.7 and 2.0 kb in length were detected, 
in addition to full-length genomic RNA (Fig. 1B). These subgenomic RNA share the 
same 3’ terminus. 
 
 
ORF1, that begins approximately 30 nt downstream of the 5´ end of the RNA, is 
5073-5124 nt long and encodes the non-structural proteins (Purcell & Emerson, 2001). 
The coding region of ORF1 contains a methyltransferase domain, Y domain, papain-like 
cysteine protease domain, proline-rich hinge or spacer region, X domain, helicase and 
RNA-dependent RNA polymerase (RdRp) domains (Koonin et al., 1992). The 
methyltransferase and RdRp activities of ORF1-encoded protein have been demonstrated 
(Agrawal et al., 2001; Magden et al., 2001). Helicase and protease activities, however, 
have not been shown yet. The functions of the Y and X domains also remain unknown. 











7.2 kb (genomic) 
3.7 kb (subgenomic) 
2 kb (subgenomic) 
B. 
M7G-cap 
Fig. 1 Genome organization of hepatitis E virus (A) and 
viral RNAs (B).  A. The HEV genome encodes three 
open reading frames.  B. The genomic RNA is capped. 
Three viral RNAs were found in the liver of 




evidenced by the presence of a 5’ cap structure on the viral genome (Kabrane-Lazizi et 
al., 1999b; Zhang et al., 2001). The RNA helicase of HEV is ~38 kDa (Panda, 2000) and 
found to contain all the conserved motifs of helicase superfamily I. The HEV helicase, as 
other helicases, probably promotes the unwinding of RNA-RNA duplexes during the 
process of genomic replication and transcription. The RdRp of HEV is about 36 kDa and 
is probably involved in early stages of viral replication (Panda, 2000). HEV RdRp 
possesses characteristics similar to that of other positive sense animal and plant viruses 
(Fry et al., 1992; Koonin et al., 1992). It was shown that the HEV RdRP specifically 
binds to the 3’ end of the viral RNA and directs the synthesis of complementary RNA 
(Agrawal et al., 2001). 
 
ORF 2 encodes the viral major capsid protein - the major viral immunogenic 
protein. The capsid protein has high basic amino acid (aa) content (Jameel et al., 1992; 
Tam et al., 1991). Both non-glycosylated (~74 kDa) and glycosylated (~88 kDa) forms of 
the capsid protein were observed in transfected cells (Jameel et al., 1992; Tam et al., 
1991). However, the functional role of the glycosylation is not known. A signal sequence 
is present at the N-terminal region of the protein (Zafrullah et al., 1999). Major epitopes 
exist in the capsid protein and ORF2 is highly conserved (Khudyakov Yu et al., 1994). 
Therefore, most serological tests are based on ORF2 product.  ORF2-endcoded protein 
has been expressed in several protein expression systems namely, E. coli (Li et al., 1997; 
Panda et al., 1995); insect cells (He et al., 1993; Li et al., 1997; Robinson et al., 1998), 





Graff et al demonstrated that a bicistronic subgenomic mRNA encodes both the 
ORF2 and ORF3 products (Graff et al., 2006). The subgenomic RNA is capped and 
initiated at nt 5122 downstream of the first two methionine codons in ORF3 and two 
closely spaced methionine codons in different reading frames were used for the initiation 
of ORF3 and ORF2 translation.  In this report, they showed that the sizes of ORF2 and 
ORF3 products of genotype 4 do not differ in size from those of other three genotypes as 
it was previously thought.  
 
ORF3-encoded protein (vp13) is a phosphoprotein that plays a major role in cell 
signaling pathways (Sehgal et al., 2006). vp13 was shown to be not necessary for 
infection of hepatoma cells in vitro (Emerson et al., 2006b). However, a recent study by 
Huang and colleagues showed that an intact ORF3 is required for infectivity in pigs 
(Huang et al., 2007). The latter group also observed that a single mutation at the third in-
frame AUG of ORF3 completely abolishes virus infectivity in vivo, indicating that the 
third in-frame AUG in the junction region is required for virus infection and is the 
initiation site for vp13. A cis-acting element at the start of the ORF is shown to be 
required for replication and this sequence is highly conserved across all four mammalian 
genotypes of HEV (Graff et al., 2006). 
 
2.4 Animal HEV and epidemiology 
HEV RNA or HEV antibodies have been found in various animal species. HEV in 
swine and in avian species have been isolated and relatively well studied. Hence, 




2.4.1 Swine HEV 
HEV infection among domestic pigs was first reported in Nepal (Clayson et al., 
1995). Subsequently, a novel swine HEV was identified and characterized(Meng et al., 
1997). Swine HEV is closely related to the human HEV. Their studies also showed that 
swine HEV is a ubiquitous agent and most of the pigs, in the Midwestern part of US that 
are 3 months or older are seropositive for swine HEV. Currently, swine HEV is endemic 
to the North American commercial swine population (Goens & Perdue, 2004). 
Epidemiological studies have also shown that swine HEV is present in various parts of 
the world (Chandler et al., 1999; Hsieh et al., 1999; Wu et al., 2000).  
 
 Pigs infected with swine HEV do not exhibit clinical signs of the disease. The 
characteristics of infection such as route of infection, transmission, virus tropism, clinical 
course, virus shedding etc. have been studied in pigs that were either naturally or 
experimentally-infected (Choi & Chae, 2003; Kasorndorkbua et al., 2004; 
Kasorndorkbua et al., 2003; Meng et al., 1998a; Meng et al., 1998b; Williams et al., 
2001). Experimentally-infected animals did not show any clinical disease or show 
abnormal levels of liver enzyme (Meng et al., 1998a). Some of these studies also showed 
that swine HEV replicates in tissues other than the liver (Williams et al., 2001). In an 
attempt to determine if pregnant pigs suffer from fulminant hepatitis, like pregnant 
women, pregnant gilts were infected with swine HEV through the intravenous route 
(Kasorndorkbua et al., 2003). However, the inoculated animals did not exhibit any 
clinical symptoms. On the other hand, studies have shown that swine HEV can infect 




of swine HEV. Indeed, some studies have also shown that swine handlers are at an 
increased risk of getting HEV infection (Meng et al., 1999; Meng et al., 2002).  
 
Swine HEV is widely present in commercial pig populations around the world. 
And, swine HEV is genetically and antigenically closely-related to human HEV genotype 
3. Collectively, these findings not only emphasize the zoonotic potential of swine HEV 
but also its adverse implications in xenotransplantations. Hence, there is an increased 
need for research on swine HEV, especially with respect to its zoonotic potential. Since 
swine HEV is ubiquitous and the infected-animals appear apparently normal without 
much decrease in their productivity, there is no immediate demand for development of 
diagnostics or vaccines. 
 
2.4.2 Avian HEV 
 A novel HEV was isolated from US chickens suffering from hepatitis-
splenomegaly syndrome (Haqshenas et al., 2001). The virus was found to be closely 
related to, but distinct from, other HEVs and was named avian HEV. The individual 
genes of avian HEV were found to show 47-61% amino acid identities with those of 
other HEVs (Haqshenas et al., 2001). The complete genomic sequence of an avian HEV 
was first published in 2004 and  found to be 6654 nt long, 600 nt shorter than human and 
swine HEVs (Huang et al., 2004). The isolates of avian HEVs also exhibit considerable 
sequence divergence among themselves (Billam et al., 2007; Sun et al., 2004a). Unlike 
swine HEV, avian HEV was unable to infect and produce disease in non-human primates 
(Huang et al., 2004). However, avian HEV was able to infect and seroconvert turkeys 




vice versa. Serological studies show that avian HEV is widespread in the US poultry 
population (Huang et al., 2002b). Avian HEV is also detected in a layer flock in Ontario, 
Canada (Agunos et al., 2006). 
 
 It is believed that as in the case of swine HEV, avian HEV might also cause 
inapparent subclinical infections in chickens. Avian HEV seems to produce disease in 
older birds, especially broiler breeders, from 30 to 72 weeks of age. Affected birds 
showed enlarged liver and spleen, regressed ovaries and red abdominal fluid (Riddell, 
1997). Infected young birds, on the other hand, usually did not show any clinical 
symptoms (Sun et al., 2004a; Sun et al., 2004b). A systematic study was conducted to 
assess the pathogenesis and replication of avian HEV in experimentally-infected birds 
(Billam et al., 2005). The authors observed that the virus was able to produce gross and 
microscopic lesions in the liver and was able to produce slight increase in liver enzyme 
levels (Billam et al., 2005). A recent attempt to study vertical transmission of avian HEV 
has shown that though the virus is present in the egg white, there is no evidence of 
vertical transmission for avian HEV (Guo et al., 2007a). It is interesting to note that 
though human HEV has been observed to exhibit vertical transmission, both swine and 
avian HEV do not show such transmission. Since avian HEV is a newly identified agent 
and does not seem to cause clinically important disease in birds, very few research efforts 
have been taken for developing vaccines or other control measures. The only study till 






2.5 Pathogenesis and pathology 
Most of the knowledge currently gained regarding the pathogenesis and pathology 
of HEV has largely been through experimental infections of animals. Infection is 
primarily through the feco-oral route. However, parenteral routes of infection have also 
been postulated (Arankalle & Chobe, 1999; Khuroo et al., 2004; Wang et al., 1993). 
HEV infections are usually acute with no chronic states.  The virus is presumed to 
replicate primarily in the liver (Tsarev et al., 1992) . With fecal-oral transmission, 
jaundice occurs after a short viremic period and elevated serum alanine transaminase 
(ALT) levels (Jameel, 1999). Clinical symptoms occurs at this stage and includes 
jaundice, anorexia, hepatomegaly, abdominal pain and tenderness, nausea and vomiting 
and fever (Goens & Perdue, 2004). The incubation period ranges from 3 to 8 weeks with 
an average of 40 days (Purcell & Emerson, 2001; Yarbough, 1999). The virus is excreted 
in bile and passed out in feces, which then serves as a source of infection for new 
individuals.  
 
Experimental infection of non-human primates with HEV has also led to 
important information about the course of illness, virus excretion, changes in liver 
enzyme profile, histological changes in liver etc. (Arankalle et al., 1995). HEV infections 
have very low mortality rate of about 1% in normal individuals, but higher than those 
with HAV infections, 0.2% (Goens & Perdue, 2004). However, in pregnant women the 
mortality can reach as high as 20%, which is believed to be due to an abnormal immune 





Major histopathological changes that occur during HEV infections are focal 
necrosis, similar to those in drug-associated toxicity, with minimal infiltration of 
inflammatory cells (Purcell & Emerson, 2001; Tsarev et al., 1994). The liver lesions are 
assumed to be immunologically mediated rather than virus-induced damage (Emerson 
and Purcell, 2006). Two important histological features of HEV infection considered to 
differentiate hepatitis E from hepatitis A are the development of chronic cholestasis and, 
the tendency of liver parenchymal cells to organize in pseudoglandular formations 
(Goens & Perdue, 2004; Purcell & Emerson, 2001). As it is presumed that the virus 
replicates in the liver, HEV is subsequently found in bile, in large quantities (Purcell & 
Emerson, 2001; Tsarev et al., 1992). From the bile, it is passed out in feces, which then 
serves as a source of infection for new individuals. The shedding precedes the onset of 
clinical signs, coinciding with increasing serum ALT and the progression of clinical signs 
(Jameel, 1999; Tsarev et al., 1992). In experimental infections of macaques, anti-HEV 
IgM is detected approximately 3-4 weeks after infection and continued to be detectable 
up to 3 months (Tsarev et al., 1994). Further, these findings are consistent with reports in 
humans (Emerson & Purcell, 2003; Jameel, 1999; Purcell & Emerson, 2001). Following 
IgM, anti-HEV IgG is detected which peaks several weeks later and can be detected for 
many months and years after infection (Arankalle et al., 1999; Yarbough, 1999). In 
chronic liver disease patients, acute HEV infection can trigger severe liver 






The characteristic feature of HEV infection when compared to other hepatitis 
viral infections is the increase in incidence of fulminant hepatic failure (FHF) 
complicated by encephalopathy and disseminated intravascular coagulation in HEV-
infected pregnant women (Jameel, 1999; Khuroo & Kamili, 2003; Madan et al., 1998). 
The disease severity increases with the gestation and is reflected by increased mortality 
rate (Khuroo & Kamili, 2003; Singh et al., 2003). Vertical transmission rates range 
between 30-100% (Khuroo et al., 1995; Kumar et al., 2001; Singh et al., 2003). FHF 
could not be reproduced in pregnant monkey models, however (Purcell & Emerson, 
2001). A Schwartzman-like phenomenon refers to the disseminated intravascular 
coagulation occuring from a second endotoxin assault. The phenomenon is worsened by 
the reticuloendothelial blockage and has been accounted for the FHF in HEV-infected 
pregnant women. It has been shown that pregnant women are sensitive to such an 
endotoxin-mediated effect (Goens & Perdue, 2004). Recently, it has been reported that 
the high mortality rate in pregnant women is associated with immunological changes, 
which include downregulation of the p65 component of nuclear factor  kappa B and a 
predominant T-helper type 2 (Th2) bias in the T cell response (Navaneethan et al., 2008). 
Understanding the biology of HEV is needed to know about the detailed pathogenesis of 
FHF in pregnant women.   
 
2.6 Public health concern 
Water-borne transmission of HEV is considered one of the major routes of 
transmission of HEV and, most surveys have shown that fecally-contaminated drinking 




from a study on the prevalence of HEV in water showed that one of five pretreatment 
sewage samples collected from Washington, DC was positive for HEV by RT-PCR 
(Mushahwar, 2008). Recent reports have also shown that transmission is not only through 
fecal-oral but also through ingestion of  undercooked infected meat (swine or wild 
animals) or through infected blood products (Bihl & Negro, 2008).   
 
            It is now strongly believed that HEV is a zoonotic pathogen. The possibility that 
swine hepatitis E virus can infect humans poses risks in xenotransplantations. In Japan, 
the first direct evidence of zoonotic transmission of HEV was documented in two 
outbreaks involving human consumption of raw wild boar liver and raw deer meat; one 
patient died (Tei et al., 2003; Yazaki et al., 2003).  HEV was found in 1.9 percent of 363 
packages of raw pork liver from grocery stores in Japan and one HEV isolate from 
packaged liver was identical in sequence to the HEV isolated from a patient with hepatitis 
(Yazaki et al., 2003). It was also demonstrated that Hepatitis E was transmitted by blood 
transfusion from a donor infected via the zoonotic food-borne route (Matsubayashi et al., 
2004). Anti-HEV antibodies have been detected in a number of animal species including 
pigs (Clayson et al., 1995; Favorov et al., 2000; Meng et al., 1998a; Meng et al., 1997), 
cattle (Favorov et al., 2000), sheep (Favorov et al., 2000), goats (Favorov et al., 2000), 
horses (Saad et al., 2007), rodents (He et al., 2002; Kabrane-Lazizi et al., 1999a; Karetnyi 
Iu et al., 1993), and cats (Okamoto et al., 2004), suggesting that there could be a large 
animal reservoir of HEV. Meng et al. (Meng et al., 2002) reported that swine 
veterinarians were one and a half times more likely to seroconvert to HEV infection, 




was a 5.4 times increased risk to people exposed to swine than unexposed for HEV 
infection (Galiana et al., 2008). Workers in wastewater treatment plants were also found 
to have antibodies to HEV (El-Esnawy et a., 1998). All these data demonstrate the 
zoonotic implications of HEV infection. Moreover, autochthonous HEV infections in 
developed countries may be due to zoonotic infection (Christensen et al., 2008; 
Matsubayashi et al., 2004; Wichmann et al., 2008). Normally, HEV infections are acute 
and self-limiting, but several reports have shown persistent HEV infection with chronic 
hepatitis and cirrhosis in patients with reduced immune surveillance due to chemotherapy 
or post-transplant immunosuppression (Bihl & Negro, 2008; Gerolami et al., 2008; 
Haagsma et al., 2008; Schildgen et al., 2008).  
 
2.7 Diagnosis 
Diagnosis of HEV is usually based on epidemiological characteristics of the 
outbreak and by exclusion of other liver diseases such as hepatitis A and B. Also, if any 
travel to HEV endemic region was involved, HEV should be suspected (Goens & Perdue, 
2004). Similarly, increased incidence of fulminant hepatitis during pregnancy and water-
borne outbreaks probably indicates HEV infection (Hamid et al., 1996). Commercial test 
kits to detect IgG and IgM antibodies to HEV are available in Europe, Asia and Canada, 
but not in USA (Emerson et al., 2006a). Though immunoelectron microscopy is an ideal 
method to detect virus particles in fecal specimens, it is still not a very sensitive test 
(Ticehurst et al., 1992). Molecular methods such as RT-PCR using specific primers are 
also useful in detecting viral RNA in serum, fecal or environmental samples such as 




use recombinant proteins or synthetic peptides representing antigenic domains from 
ORF2 and ORF3. Ahn et al. (Ahn et al., 2006) observed that real-time RT-PCR was more 
sensitive than conventional RT-PCR. Recently, a microarray-based nano-amplification 
technique was developed as a rapid means to detect HEV (Liu et al., 2006). However, 
serological methods still remain the best choice to detect HEV (Emerson et al., 2006a), 
given the low sensitivity and laborious nature of immunoelectron microscopy (Goens & 
Perdue, 2004). And the sensitivity of the real time RT-PCR technique depends on a 
proper match between the HEV strain and the PCR primers used in the assay. 
 
2.8 Treatment, prevention and control 
No specific treatment is available. General treatment is usually supportive. 
Currently there is no vaccine available for HEV control. ORF2 product contains 
important epitopes that can induce neutralizing antibodies and has been the focus for 
vaccine development (Purcell et al., 2003). Tsarev and colleagues found that both 
passively and actively acquired anti-HEV antibodies can protect cynomolgus monkeys 
(Tsarev et al., 1994).  Two doses of HEV vaccine containing recombinant HEV capsid 
protein (56 kDa) expressed in insect cells partially protected rhesus monkeys from 
hepatitis E following intravenous challenge 6 or 12 months after vaccination (Zhang et 
al., 2002). Different fragments of ORF2 were evaluated in their ability to protect rhesus 
monkeys against acute hepatitis. All  three fragments used in the study were found to 
protect the challenged animals (Ma et al., 2002). Partial ORF2 was expressed in 
transgenic tomatoes and the recombinant antigens derived from them were found to have  




particles containing HEV ORF2 gene into mice intramuscularly induced immune 
responses to both HEV and human papilloma virus (Renoux et al., 2008). Recently, in a 
study that used a combined vaccine for HAV and HEV, the inactivated HAV component 
of the vaccine was observed to increase the immunogenicity of HEV recombinant protein 
component (Dong et al., 2007). A candidate vaccine containing recombinant ORF2 
protein has currently passed phase II trial in Nepal, the region endemic to HEV infection. 
The vaccine contains the purified polypeptide produced in insect cells infected with a 
recombinant baculovirus containing a truncated ORF2 protein. It was found to be safe 
and immunogenic in volunteers in Nepal (Shrestha et al., 2007). It was noted that virus-
like particles from HEV capsid protein were not used in this study though the capsid 





Chapter 3: Introduction and Research Objectives 
 
3.1 Introduction on HEV ORF3 
HEV ORF3 encodes a phosphoprotein (vp13) with an approximate molecular 
mass of 13 kDa (Tam et al., 1991). vp13 has not been found in HEV virions. Recently, it 
was reported that a monoclonal antibody against vp13 reacted with  HEV virions released 
from infected cells, but not the virions in feces (Takahashi et al., 2008), which needs to 
be confirmed. The translation of ORF3 is initiated at the third in-frame initiation codon 
AUG, 23 bases downstream of the termination codon of ORF1 (Graff et al., 2006; Huang 
et al., 2007). ORF3 also contains the cis-reactive element at 5’end, which is essential for 
infectivity of macaques and pigs. Most of the knowledge about HEV vp13 has been 
obtained mainly from overexpression of the protein in cells transfected with the vp13 
expression plasmid. The exact functions of vp13 in HEV infection remain unclear though 
a number of studies have found that it may play a role in cellular signaling pathways 
(Kar-Roy et al., 2004; Korkaya et al., 2001; Moin et al., 2007; Tyagi et al., 2002; Tyagi 
et al., 2005; Tyagi et al., 2004; Zafrullah et al., 1997). 
 
The HEV vp13 was also detected as a dimeric form of 26-28 kDa in size in in 
vitro expression (Zafrullah et al., 1997). It may be because that vp13 can form 
homodimers through a C-terminal 43-amino-acid interaction domain (Tyagi et al., 2001). 
The dimerization domain overlaps with the SH3 binding and phosphorylation site, 
indicating that it may play a role in signal transduction pathways. The N-terminal portion 




terminus contains proline rich residues (Zafrullah et al., 1997). The C-terminal half of 
vp13 contains a src homology 3 binding domain and MAPK site. vp13 activates MAPK 
and ERK, and binds but does not activate Src kinase via its proline-rich domain (Kar-Roy 
et al., 2004; Korkaya et al., 2001). Furthermore, vp13 also interacts with other SH3 
domain containing proteins that are upstream modulators of important mitogenic 
signaling pathways involved in cell survival. A recent report showed that vp13 inhibits 
epidermal growth factor receptor (EGFR) trafficking and STAT3 nuclear translocation, 
suggesting a role for vp13 in promoting cell survival (Chandra et al., 2008). In an ORF3-
expressing stable Huh-7 cell line, vp13 was able to protect the cells from mitochondrial 
depolarization and death by upregulation of voltage-dependent anion channel gene and 
hexokinase I (Moin et al., 2007). However, siRNA-mediated knockdown of ORF3 gene 
in the stable cells led to only slight reduction of the number of cells that survived 
staurosporine-induced cell death. Collectively, these data suggest that vp13 may 
contribute to HEV pathogenesis by promoting cell survival.  
 
Deletion and site-directed mutagenesis studies found that Ser-80 was the 
phosphorylation site for vp13 by mitogen-activated protein kinase (MAPK) (Zafrullah et 
al., 1997). The phosphorylated form of vp13 has been shown to interact with non-
glycosylated form of the major capsid protein encoded by ORF2 (Tyagi et al., 2002).  But 
it was found that this phosphorylation site was not required for HEV replication in 
experimental infection of monkeys as a mutant HEV replicon lacking this site still caused 





Yeast two-hybrid system was used to screen a human liver cDNA library for 
proteins interacting with ORF3. vp13 was found to interact with Bikunin, a serine 
protease inhibitor with immunosuppressive property and to hemopexin, an acute phase 
protein with inflammatory role (Tyagi et al., 2005). One of the other ORF3-interacting 
partners isolated and identified is hemopexin, a 60 kDa acute-phase plasma glycoprotein 
with a high binding affinity to heme (Ratra et al., 2008). Hydrophobic domain II was 
found to be responsible for the interaction. These findings suggest that vp13 may act as a 
viral regulatory protein. Together, all these data indicate the multifarious roles played by 
vp13 in HEV pathogenesis and highlight the need to characterize further the functions of 
vp13.  
 
In addition to its presumed role in cell signaling, HEV vp13 has also been found 
to be associated with the cytoskeleton. In vp13-transfected COS-7 cells, vp13 was found 
to partition with the cytoskeletal fraction (Zafrullah et al., 1997). Deletion of N-terminal 
hydrophobic domain of vp13 abolished this association. However, the nature of 
interaction and the vp13-binding proteins required for this association are not known. 
 
Due to lack of efficient cell culture for HEV propagation, functional study of 
vp13 in HEV biology and infection is limited. It was reported that vp13 is essential for 
HEV infection in Macaques and pigs (Graff et al., 2005; Huang et al., 2007). An 
infectious cDNA clone of HEV was used to study the roles of ORFs 2 and 3 in HEV 
replication and infection (Graff et al., 2005). A frame-shift mutation at the 5’terminus of 




produce a detectable infection in rhesus macaques (Graff et al., 2005), indicating the 
requirement of ORF3 for HEV infection. A mutant with a C-terminally truncated ORF3 
of swine HEV infectious clone was not infectious in pigs and a single mutation at the 
third in-frame AUG of ORF3 abolished the virus infectivity in vivo, indicating the ORF3 
product is essential for HEV infection (Huang et al., 2007). These experiments 
demonstrated that HEV vp13 may play an essential role in HEV infection. Further 
investigation is warranted to elucidate the mechanisms.   
 
Therefore, to further study vp13, we performed preliminary study on vp13 
subcellular location and found that vp13 expression co-localizes with cellular 
microtubules. To further confirm the interaction of vp13 with microtubules and 
understand the mechanisms and potential consequences, we conducted further 
experiments to provide more insights on the multifarious roles of vp13 and thereby 
advance our understanding of HEV pathogenesis. This study was conducted to examine 
vp13 subcellular location, the functional significance of the vp13 association with the 
cytoskeletal network, the cellular binding partners required for this association, nature of 
the interaction and, the effects of this association. 
 
3.2 Research objectives  
The specific objectives in the present study on vp13 protein of HEV are:  
 1. To define the interaction of vp13 protein with microtubules (MT)  





Chapter 4: Materials and Methods  
  
4.1 Cells. 
Cell lines HeLa, COS-7, and Huh-7 were maintained at 37°C in Dulbecco’s 
Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and penicillin-streptomycin mixture and L-glutamine. Huh-7 cells are human hepatoma 
cell line.  
  
4.1.1 Establishment of vp-13 expressing stable cell line 
Cells that have stable expression of vp13 would be more suitable for 
characterizing HEV vp13 than those that only have transient expression of vp13. 
Therefore, we generated HeLa cells stably-expressing vp13. Briefly, HeLa cells grown to 
confluence were transfected with VenusN1-H3 plasmid using FuGeneHD (Roche 
Diagnostics, Indianapolis, IN). After 24 h, the cells were trypsinized and seeded into a 60 
mm tissue culture plate at a density of 30,000 cells/ml and were grown under G418 (400 
µg/ml) selection. Resistant clones that expressed vp13 fusion protein were selected by 
live fluorescent microscopy and the positive clones were expanded under G418 selection. 
Two clones were finally selected for this study. Western blot analysis with GFP- and 
vp13-specific antibodies showed that both clones had high level expression of vp13 
protein. PCR amplification and sequencing confirmed the presence of intact ORF3 







4.2 Chemicals and antibodies 
Microtubule destabilizing drug nocodazole (NOC), dynein inhibitor sodium 
vanadate (Na3VO4), Taxol and Trichloroacetic acid (TCA) were purchased from Sigma, 
St Louis, MO. ATP and GTP were purchased from Promega. For all experiments 
involving NOC treatment, the cells were treated with the drug at a concentration of 10 
µM for 4 h. Taxol was used at a concentration of 40 µM. Sodium vanadate was used at a 
concentration of 100 µM. 
  
Antibody against HEV vp13 was a kind gift from Dr. X-J Meng (Virginia 
Polytechnic Institute and State University, Blacksburg, VA). Commercially-available 
antibodies were used for other proteins tested for in this study – β-tubulin, GFP, p53, and 
FLAG (Sigma); p21Cip1/WAF1 (Invitrogen); PARP, caspase-8 and -9, and acetylated α-
tubulin (Santa Cruz Biotechnology, Santa Cruz, CA); dynein (Millipore). 
 
4.3 Plasmids and vectors 
 The plasmid pSK-E2 that contains the full length cDNA of HEV genome was a 
generous gift from Susane Emerson, NIAID, NIH (Emerson et al., 2001). VenusN1 and -
C1 vectors that contain an improved version of yellow fluorescent protein named 
“Venus” were kind gifts from Ioanis Bossis, University of Maryland, College Park 
(Nagai et al., 2002). The N1 and C1 nomenclature of the Venus vector denotes the 
presence of the cloning site upstream and downstream of the Venus gene, respectively. 
The plasmid pCMVTag2 vector, used for the expression of FLAG-tagged fusion protein 




construct was a kind gift from Richard Vallee, Columbia University, New York, NY 
(Echeverri et al., 1996). 
 
4.4 Transfection 
Transfection experiments were performed on cells grown to 90-95% confluence 
in 12-well plates. The cells were transfected with 2 µg of the vp13 expression plasmid or 
a similar amount of empty vector in a volume of 100 µl of Opti-MEM (Invitrogen) per 
well. Transfection was carried out with FuGeneHD (Roche Diagnostics, Indianapolis, 
IN), according to the manufacturer’s instructions. Cells treated with only the transfection 
reagents served as mock-treated controls. Cells were harvested at 24 h after transfection, 
unless otherwise specified and utilized for further analysis. 
 
4.5 Construction of vp13 plasmids.  
HEV ORF3 was amplified from pSK-E2 by PCR using Venus N1-H3 For and 
Venus N1-H3 Rev primers (Table 1) that contain restriction sites of EcoRI and BamHI, 
respectively. The forward primer was designed to begin from the third in-frame initiation 
codon AUG in ORF3 that was recently found to be an authentic translation initiation 
codon for this gene (Huang et al., 2007). The PCR-amplified product was digested with 
the two enzymes, and then ligated to a VenusN1 vector, using T4 DNA ligase (Promega), 
upstream of the Venus reporter gene. The ligation mixture was transformed into DH5α 
competent cells and positive clones were selected by PCR. Cloning was further 
confirmed by restriction enzyme digestion and bidirectional nucleotide sequencing using 




VenusN1-H3, was used in the following studies. The ORF3 gene was also similarly 
cloned into VenusC1 vector to confirm the expression pattern.  
 
The ORF3 gene was also cloned into pCMVTag2 vector for expression of FLAG-
tagged fusion protein in mammalian cells. PCR primers used for the cloning were 
designed similarly as above to include restriction enzyme sites and make sure ORF3 gene 
was in-frame with FLAG sequence in the vector. The presence of ORF3 gene in the 









Fig 2. Construction of HEV ORF3 expression plasmids. The ORF3 of HEV (H3) was 
cloned into Venus N1 vector, upstream of the Venus reporter gene (N1-H3) using the 
indicated restriction enzymes. Similarly, H3 was also cloned into Venus C1 vector, 
downstream of the Venus reporter gene (C1-H3). Additionally, H3 was also cloned into 




Table 1. Oligonucleotides used in construction of ORF3 expression plasmids 
 
All the forward primer sequences contained restriction site for EcoRI enzyme (italicized 
and underlined), while all the reverse primer sequences contained restriction site for 
BamHI enzyme (underlined).  
 
 
Plasmid Primer sequence (5′ to 3′) 
For – GCGAATTCATGGGTTCGCGACCATGCG Venus N1-H3 
Rev – CCGGATCCTTGCGGCGCGGCCCCAGCTGTG 
 
For – GCGAATTCAATGGGTTCGCGACCATGC 
 
Venus C1-H3 
Rev – CCGGATCCTTGCGGCGCGGCCCCAGCTGTG 
 




Rev – CAGGATCCGTTGGTTGGATGAATATAG 
 




Rev – CTGGATCCCTGGTCACGCCAAGCGGA 
 




Rev – CCGGATCCTTGCGGCGCGGCCCCAGCTGTG 
 




Rev – CCGGATCCTTGCGGCGCGGCCCCAGCTGTG 
 








Various truncation mutants of ORF3 were constructed by cloning fragments of 
ORF3 into Venus vector (Fig 3). Primers were designed accordingly to amplify the 
individual fragments of ORF3 by PCR (Table 1). Cloning was performed, in a manner 
similar to that of full length ORF3, into VenusN1 or Venus C1 vectors.  
 
 
Fig 3. Schematic illustration of ORF3-truncation plasmids. The numbers above each line 
indicate starting and ending nucleotides of ORF3 or truncations. H3 contains the full-
length vp13. H3D1 contains both hydrophobic domains at N-terminal end of vp13, but 
lacks a stretch of 49 aa residues at its C-terminal end. H3D2 contains both the 
hydrophobic domains at the N-terminal region, but lacks 15 aa residues at its C-terminal 
end. H3D3 lacks the first N-terminal hydrophobic domain but contains the second 
hydrophobic domain of vp13. H3D4 lacks both the hydrophobic domains while the 





4.6 Fluorescence microscopy.  
Cells were seeded directly onto cover slips in cell culture plate, incubated 
overnight, and transfected the next day. Twenty-four hours post transfection, the cells 
were observed directly under fluorescence microscopy (Venus vector-transfected cells) or 
fixed with 1% paraformaldehyde and mounted onto slide with anti-fade mounting 
solution (Invitrogen, Carlsbad, CA) before observation. For the cells treated with NOC, 
culture medium was replaced with medium containing the drug at 24 h post transfection 
and the cells were incubated for an additional 2 h. The NOC was then removed and 
washed twice with PBS, and were observed under fluorescence microscopy. For studying 
the recovery from NOC-treatment, the treated cells were further incubated for 4 h with 
culture medium after the removal of NOC-containing medium.   
 
Immunofluorescence assay (IFA) was carried out as reported previously (Zhang et 
al., 1998) with an rabbit anti-vp13 antibody. A FITC conjugated goat anti-rabbit IgG 
(Invitrogen) was used to detect vp13 by fluorescent microscopy.  
 
4.7 Western blot analysis.  
HeLa cells were transiently transfected with VenusN1-H3 or empty vector. At 24 
h post transfection, the cells were lysed with Laemmli sample buffer. SDS-PAGE and 
Western blot analysis were performed as described previously (Zhang et al., 2007). 
Briefly, the cell lysates were electrophoresed on 12% SDS-polyacrylamide gels. The 
separated proteins were transferred onto nitrocellulose membrane and probed with rabbit 




conjugated with horseradish peroxidase (Sigma) and the addition of chemiluminescence 
substrate. Chemiluminescence signal was collected by a ChemiDoc XRS imaging system 
(Bio-Rad Laboratories, Hercules, CA). Beta-Tubulin was detected on the same blot 
membranes to normalize protein loading in the analysis. Digital image acquisition and 
densitometry analyses were conducted using Quantity One software (Bio-Rad).  The 
expression of other proteins, tested in this study, was detected in a similar manner using 
corresponding antibodies. 
 
4.8 Cell viability assay.  
Cell viability was determined with CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega, Madison, WI). Briefly, cells were cultured in 96-well plate and 
CellTiter-Glo reagent was added and incubated for 10 minutes at room temperature. The 
luminescence signal was measured with VICTOR3™ Multilabel Counter (Perkin-Elmer, 
Waltham, MA). Relative percentages of luminescence intensity were calculated by 
comparison to mock-treated controls. All experiments were performed at least in 
duplicates and were repeated at least three times. 
 
4.9 Caspase-3 and -7 activity detection.  
  Caspase-3 and -7 activities in the transfected cells were detected using Caspase-
GloTM 3/7 Assay kit (Promega), as the manufacturer’s instructions. Briefly, 50 µl of 
Caspase-Glo reagent was added to each well containing the cells in 50 µl of culture 
media and incubated for 30 minutes at room temperature. The luminescence signal was 




relative percentages of luminescence intensity were calculated. All caspase assays were 
performed at least in duplicates and were repeated at least three times. 
 
4.10 Real-time PCR.  
Total RNA was isolated from cells lyzed in TRIzol® Reagent (Invitrogen), 
according to manufacturer’s instructions. For quantitative RT-PCR analysis, RNA was 
first treated with RNase-free DNase (Promega) to remove carryover DNA from the RNA 
isolation procedure. Random-hexamer-primed reverse transcription was carried out using 
AMV reverse transcriptase (Promega). Primers for real-time PCR were designed based 
on cDNA sequences of target mRNA. Real-time PCR with SYBR Green detection was 
done as described previously (Patel et al., 2008). The results depicted are averages of 
three independent experiments. 
 








For - 5’ TCAACAAGATGTTTTGCCAACTG 3’  
Rev - 5’ ATGTGCTGTGACTGCTTGTAGATG 3’  
 
For - 5’ ATGAAATTCACCCCCTTTCC 3’ 






4.11 MT isolation and salt-extraction assay.  
MT isolation and salt-extraction assays were performed as described previously, 
with some modifications (Goode & Feinstein, 1994; Pipeleers et al., 1977). Briefly, HeLa 
cells were transfected with C1-H3 DNA and at 24 h post-transfection lysates were 
collected with MT stabilization buffer (100 mM PIPES pH6.9, 5 mM MgCl2, 1mM 
EGTA), both with and without the addition of ATP and GTP. Taxol (40µM) was 
included to artificially stabilize the MT. Cell lysates were collected with a cell scraper, 
transferred to a centrifuge tube, and homogenized with a syringe and 25-gauge needle. 
After 10 min of incubation at 37°C, 2µl of the sample was mixed with trypan blue, and 
checked for at least 95% cell lysis. The sample was then centrifuged at 100,000g for 30 
min at 37°C, using buffers and rotors pre-warmed at 37°C. After centrifugation, the 
supernatant was transferred to a pre-chilled tube and the pellet was resuspended with salt 
extraction buffer (80 mM PIPES pH6.9, 1 mM MgCl2, 1mM EGTA, and 500 mM KCl). 
Taxol was added at 40 µM and the sample was centrifuged again at 100,000 xg for 30 
min at 37°C. After centrifugation, the supernatant was transferred to a pre-chilled tube. 
The pellet was resuspended in MT stabilization (MTS) buffer and then boiled in 1X SDS-
PAGE sample buffer and heated at 95°C for 2 min. The supernatants were precipitated 
with TCA and then analyzed by SDS-PAGE and Western blot using antibodies against 
vp13, acetylated α-tubulin and β-tubulin. For experiments with addition of detergent in 
lysis buffer, the cells were lyzed in buffer PEMT (100 mM PIPES pH6.9, 5 mM MgCl2, 1 
mM EGTA, 0.1%Triton, 0.1%Tween20, 0.001% Antifoam). Cell homogenization and 









Fig 4. MT isolation and salt extraction assay. MTS buffer – MT stabililizing buffer; SDS 




Chapter 5: Results  
 
5.1 HEV vp13 protein co-localizes with the MTs.  
HEV ORF3 (H3) was first cloned into VenusN1 vector for expression of vp13-
venus fusion protein. HeLa cells were transfected with VenusN1-H3 plasmid. At 24 h 
after transfection, live fluorescence microscopy was conducted. Under high 
magnification (40X and 63X) and a FITC filter, green filamentous structures were 
observed in the HeLa cells (Fig 5), indicating the expression pattern of vp13 fusion 
protein and its probable co-localization with MTs. When the cells were fixed with 
paraformaldehyde, the expression pattern of vp13 fusion protein was unaltered. There 
was also punctate distribution in the cytoplasm. In contrast, homogeneous bright green 
fluorescence in both cytoplasm and nucleus was observed in cells transfected with empty 
vector (Fig 5).  
 
To determine if the position of H3 in the fusion protein affected its expression 
pattern, H3 was cloned into VenusC1 vector that contains the cloning site downstream of 
the Venus gene. Transfection of HeLa cells with VenusC1-H3 plasmid also showed the 
same pattern as vp13-venus fusion protein described above, but with much more intense 
fluorescence (Fig 5b), indicating that the location of the vp13 protein on the Venus vector 
did not affect or alter the expression pattern. Cells transfected with the empty vector had 
homogeneous bright green fluorescence in both cytoplasm and nucleus, as observed with 





In order to evaluate if vp13 expression pattern differs with the nature of 
expression vector used, H3 was also cloned into PCMV vector. Following transfection of 
HeLa cells with this construct, we observed a similar expression pattern by 
immunofluorescence assay (Fig 5c). These results indicated that the nature of the vector 
used to express the vp13 gene did not alter the expression pattern of vp13 in transfected 
cells.  
 
To determine if the expression of HEV vp13 protein was similar in hepatoma cell 
line since hepatocytes are the primary target cells of HEV, Venus C1-H3 plasmid was 
transfected into Huh-7 cell line. Green fluorescence of filamentous pattern was also 
observed in Huh-7 cell line (Fig 6). The expression of vp13 fusion protein in Huh-7 cells 
appeared in a pattern similar to HeLa cells (Fig 5), though at a lower rate. Therefore, 
HeLa cells were used in all subsequent experiments, unless otherwise specified, for 
assessing vp13 co-localization with MTs.  
 
The vp13 fusion protein expression was also detected by Western blot analysis 
with an antibody against GFP. The size of the vp13-venus fusion protein was ~ 40 kDa, 
while Venus protein alone was 27 kDa (Fig 7A). To further confirm the expression of the 
vp13 fusion protein, a rabbit antibody against HEV vp13 was used in Western blot and 
the band at expected size was detected, while no bands were visible in lysates from 
vector- or mock-transfected cells (Fig 7B). These results confirmed the expression of 




The expression of vp13 in HeLa cells transfected with pCMV-H3 plasmid was 
confirmed by Western blot analysis with rabbit anti-vp13 antibody. Since ORF3 was 
cloned into pCMVTag vector for expression of FLAG-tagged vp13 fusion protein, we 
also performed Western blot with FLAG antibody. However, no specific signal was 
detected (data not shown), which indicated that the vp13 expression in HeLa cells 
transfected with pCMV-H3 was not a FLAG-tagged fusion protein. DNA sequencing 
confirmed that the full-length ORF3 with initiation codon was in frame with FLAG 
sequence in the plasmid. Thus, it was speculated that the translation starts from the 
initiation codon of HEV ORF3 gene, instead of AUG upstream of FLAG tag sequence. 







Fig 5. Interaction of vp13 with MT in HeLa cells. Cells were transfected with Venus N1-
H3 (A) or Venus C1-H3 (B), pCMV-H3 vectors and, observed by live fluorescence 
microscopy (A&B) or immunofluorescence (C). Note the filamentous pattern of the vp13 























Fig 6. Interaction of vp13 with MT in Huh-7 cells. Huh-7 cells were transfected with 
Venus N1-H3 and, observed by fluorescence microscopy. Note the filamentous pattern of 









Fig 7. Detection of vp13 fusion protein by Western blot. HeLa cells were transfected with 
VenusN1-H3, and cell lysates were detected for the expression of vp13 fusion protein by 
Western blot using mouse anti-GFP antibody (A) or rabbit anti-vp13 antibody (B). Cells 
transfected with the empty vector or untransfected cells were included as controls. M: 





5.2 Effect of MT-depolymerizing agents on HEV vp13 expression pattern. 
The pattern of expression of vp13 in the transfected cells indicated that it co-
localizes with MTs. To explore the association of vp13 with the microtubular 
cytoskeleton, we used a reversible MT-destabilizing drug nocodazole (NOC) on vp13-
expressing cells and then observed the expression pattern of vp13. HeLa cells were 
treated with NOC at a non-toxic concentration of 10 µM for 4 h on day 2 after 
transfection with VenusN1-H3 plasmid. When observed by fluorescence microscopy, we 
found that the drug treatment led to disappearance of the filamentous expression pattern 
of vp13 (Fig 8). Green punctate fluorescence was observed along the cell periphery or 
subcellular organelles (Fig 8, top panel).  
 
The effects of NOC are reversible. Therefore, to test if the removal of NOC from 
the cells would restore the vp13 filamentous expression pattern, we washed the cells 
twice with culture medium and observed the cells after 4 h incubation without the NOC. 
Upon removal of NOC, the characteristic green filamentous structures were observed in 
the cells, indicating restored MT nucleation and confirming the co-localization of vp13 
with MTs. Together, these results clearly demonstrated that the expression pattern of 






















Fig 8. Effect of nocodazole (NOC) on vp13 expression pattern. HeLa cells were 
transfected with VenusN1-H3 plasmid and treated with (top) or without (bottom) the MT-
destabilizing drug NOC for 4 h on day 2 after transfection. The depolymerization of MT 
abolished the filamentous expression pattern of vp13 fusion protein (top), while the 




5.3 Determination of the MT-binding region of vp13.  
After finding that vp13 protein interacts with the MT, we attempted to determine 
the region in vp13 that was required for this interaction. We generated four truncated 
versions of ORF3 by PCR and cloned them into Venus vectors (Fig 3). Transfection of 
these plasmids into HeLa cells showed that VenusN1-H3D1 and VenusN1-H3D2 
exhibited filamentous expression pattern similar to the full length vp13 fusion protein, 
though at lower intensity (Fig 9; A, B and F). The rest two plasmids showed homogenous 
expression throughout the cells similar to patterns produced in cells transfected with 
empty vector (Fig 9; C and D). These results indicated that N' portion of vp13 was 
needed for the filamentous expression pattern.  
 
The N' portion of vp13 contains two hydrophobic domains that might be 
responsible for the MT interaction. Therefore, to further define the binding region, we 
cloned the fragment containing the first hydrophobic domain into VenusC1 vector. 
Following transfection, live-cell fluorescence microscopy was conducted and we 
observed only green punctate fluorescence but no filamentous pattern (Fig 9E), indicating 
that the first hydrophobic domain of N' region of vp13 is inadequate for MT interaction. 
Since VenusN1-H3D3 contained sequences of the second hydrophobic domain of N' 
region of vp13 and had homogeneous expression in transfected cells, the second 
hydrophobic domain is also inadequate for MT interaction either. Thus, both hydrophobic 
domains in N' region of vp13 are required for the co-localization of vp13 with MT, as 





Fig 9. Identification of MT-interacting domain of vp13 protein. Fluorescence images 
from HeLa cells transfected with the VenusN1-H3D1 (A), VenusN1-H3D2 (B), 
VenusN1-H3D3 (C), VenusN1-H3D4 (D), VenusC1-H3NH (E), and VenusN1-H3 (F) 





5.4 Effect of HEV vp13 on MT stability.  
Dynamic instability is a fundamental property of MTs and is critical for diverse 
cellular functions, and is regulated by many factors. It has been shown that persistent 
perturbation of MT dynamics with MT-stabilizing drug taxol or MT-destabilizing drug 
NOC causes significant apoptosis (Sorger et al., 1997). The taxol-perturbation of MT 
induces apoptosis through a mitochondria-dependent pathway (Wang et al., 2000).  
 
Tubulin acetylation is a well established marker of MT stability. Stable MTs 
exhibit much higher extent of tubulin acetylation than dynamic, unstable MTs 
(Westermann & Weber, 2003). Since vp13 interacts with the MTs and hyperacetylation is 
a quantitative indication of changes in MT stabilization, we examined the level of tubulin 
acetylation in HeLa cells transfected with VenusN1-H3, by Western blot using a specific 
antibody against acetylated α–tubulin (Fig 10). Compared to the controls, acetylated α–
tubulin was elevated in HeLa cells transfected with vp13 expression plasmid, pCMV-H3 
(Fig 10A). Densitometry analysis of the band intensities showed that the level of 
acetylated α–tubulin in HeLa cells with vp13 expression was 3.2-fold higher than that in 
mock-treatment control, while the cells transfected with empty vector had a little 
elevation (Fig 10B). The level of acetylated α–tubulin was also checked in Huh7 cells 
using C1-H3 vector and similar results were obtained (Fig 10C). These results indicated 
that expression of vp13 enhanced the stability of MTs, by elevating the levels of 

















Fig 10. Effect of HEV vp13 on MT stability. A. Western blot detection of acetylated α–
tubulin in HeLa cells (A) and Huh-7 cells (C) transfected with vp13-expressing plasmid 
(vp13 lane), or empty vector or untransfected (mock lane). Detection of β-tubulin in the 
same blot was conducted for normalization.  B. Graphic illustration of densitometry 
analysis of the digital image of “A”. The level of acetylated α–tubulin is presented as 
relative folds in comparison with mock-treatment control. D. Graphic illustration of 







5.5 Effect of HEV vp13 on cellular p53 levels.  
Because MT dynamics is critical for diverse cellular functions, modulation of 
MTs may result in various biological consequences. p53 tumor suppressor protein has 
been shown to associate with MTs and use the MT-dependent motor complex 
dynein/dynactin for nuclear targeting under conditions of DNA damage (Giannakakou et 
al., 2000). p53 is a key transcription factor that can induce growth-arrest, apoptosis and 
cell senescence. It is a tumor suppressor phosphoprotein that is usually inactive in normal 
cells, but becomes active after being activated by variety of stress types and oncogenes . 
So, we determined the levels of p53 in COS-7 cells expressing vp13. HeLa cells naturally 
contain an inactive p53 (Liang et al., 1995) and, therefore, were not suitable for this 
study. 
  
COS-7 cells were transfected with vp13-expressing VenusN1-H3 plasmid, or with 
empty vector or left untransfected. Lysates were harvested at 24 h post-transfection and 
subjected to SDS-PAGE and immunoblotting using a p53-specific antibody. Our results 
showed that in COS-7 cells expressing vp13, p53 level was elevated compared to those 
transfected with empty vector or untransfected cells (Fig 11A). Densitometry analysis of 
the bands showed that p53 level in the cells with vp13 expression was 2.6-fold higher 
than the vector-transfected or untransfected cells (Fig 11B). These results indicated that 
vp13 expression induced p53 elevation in COS-7 cells, while the empty vector alone did 




















Fig 11. Effect of HEV vp13 on levels of cellular p53. A. Western blot with p53 antibody. 
COS-7 cells were transfected with VenusN1-H3 plasmid (vp13), or empty vector (V) or 
left untransfected (M). Lysates were collected and subjected to SDS-PAGE and 
immunoblotting using p53-specific antibody. Tubulin was detected in the same blot for 
normalization. B. Graphic illustration of densitometric analysis of the digital image of 






To determine if the p53 elevation was due to increased p53 mRNA transcripts or 
protein accumulation, we conducted real time RT-PCR to assess p53 mRNA level in the 
COS-7 cells. In comparison with mock-treated control, cells with vp13 expression had 
more than 2.5 folds higher level of p53 transcripts (Fig 12), while empty vector did not 












Fig 12. Expression levels of p53 mRNA in vp13-expressing cells. Quantitative RT-PCR 
to assess the transcript levels of p53 was performed and the results are shown as relative 






5.6 Effect of HEV vp13 on cellular levels of p21Cip1/WAF1.  
Cyclin-dependent kinase inhibitor p21Cip1/WAF1 (p21) is transcriptionally activated 
by tumor suppressor p53. Induction of p21 is essential for p53-mediated arrest of cell 
cycle in G1 phase in response to DNA damage (el-Deiry et al., 1994). Since p53 was 
elevated in cells expressing vp13 (section 4.5), we evaluated the cellular levels of p21, 
the protein which is activated upstream by p53, in vp13-expressing cells (Fig 13). By 
immunoblotting, we found that the p21 levels in COS-7 cells expressing vp13 were 
higher than those in cells transfected with empty vector (Fig. 13A). Densitometric 
analysis showed that p21 levels in vp13-expressing cells were 2.9-fold higher than those 
in untransfected or vector-transfected cells (Fig.13B).  
 
To determine if the p21 protein elevation was due to higher transcription of p21 
mRNA, real time RT-PCR was conducted to assess p21 mRNA level in the COS-7 cells 
transfected with vp13-expressing plasmids. In comparison with mock-treatment control, 
the cells that express vp13 had 2.5-fold higher p21 mRNA level (Fig. 13C), while the 
empty vector did not lead to any change. These results indicated that the mRNA levels of 
p21 were elevated in vp13-expressing COS-7 cells, which correlated with the increased 
p21 protein levels as observed by Western blot. Taken together, these results 
demonstrated that vp13 expression led to p21 elevation, which in turn may inhibit cell 





















Fig 13. Effect of HEV vp13 on p21 expression. A. Western blot using p21 antibody. 
COS-7 cells were transfected with VenusN1-H3 plasmid (vp13), or empty vector (V) or 
left untransfected (M). Lysates were collected and subjected to SDS-PAGE and 
immunoblotting using p21-specific antibody. Tubulin was detected in the same blot for 
normalization. B. Graphic illustration of densitometric analysis of the digital image of 















Fig 13 (Contd.). C. Quantitative RT-PCR to assess the transcript levels of p21 was 
performed and the results are shown as relative fold compared with mock-treatment 
control.  
 
5.7 Effect of HEV vp13 on negative regulator of p53: MDM2.  
As described in section 5.5, our results indicated that the levels of p53 are 
elevated in vp13-expressing cells. The p53 elevation could be either due to a direct effect 
of vp13 on p53 or, due to the interference of vp13 with p53 degradation that indirectly 
leads to elevated p53 levels. MDM2 is an important negative regulator of p53 since it 
acts as an E3 ubiquitin ligase, targeting p53 for proteosome-mediated degradation 
(Kubbutat et al., 1997). Moreover, increase in MDM2 level also acts as a surrogate 
marker of nuclear localization of p53 (Giannakakou et al., 2000). Therefore, we 




(Fig 14). We could not detect any detectable increase in MDM2 protein levels in vp13-











Fig 14. Effect of HEV vp13 on MDM2 expression. Western blot for MDM2 was 
performed on lysates collected from COS-7 cells that were transfected with vp13-
expressing plasmid (H3), or empty vector (V) or left untransfected (M). Tubulin was 





5.8 Activation of apoptotic pathway by HEV vp13.  
One of the consequences of interference of MT dynamics is apoptosis, and 
activation of p53 in turn leads to activation of apoptotic responses (Vousden & Woude, 
2000). Given that vp13 interacts with MT and possibly interferes with MT dynamics by 
altering the level of acetylated tubulin, and that vp13 also increases the levels of p53, it is 
possible that vp13 expression could result in apoptosis. Therefore, we analyzed for 
various events, in vp13-expressing cells, that are characteristic of the apoptotic pathway. 
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-binding zinc finger protein 
that influences DNA repair and apoptosis (Kaufmann et al., 1993). Proteolytic cleavage 
of PARP-1 (p116) yields a cleavage product (p85) and considered as a classical hallmark 
for apoptosis. Caspases are proteolytic enzymes that are the central mediators of 
apoptosis. Therefore, we tested for the cleavage of PARP-1 and for the expression of 
caspases in cells that transiently or stably express vp13, to determine if HEV vp13 
activated the apoptotic pathway. 
 
Western blot analysis was performed to evaluate the cleavage of PARP-1 
indicated that in vp13-expressing HeLa cells. Our results indicated that cleavage of 
PARP-1 occurred at an increased level when compared to that in vector transfected or 
untransfected cells (Fig 15A). Densitometric analysis performed to determine the level of 
the cleavage product (p85), indicated that the p85 levels were about 4-fold higher in 
vp13-expressing HeLa cells compared to those in the vector-transfected cells (Fig 15B). 
To further determine the effect of vp13 on apoptosis, we generated HeLa cells that 




observed PARP-1 cleavage in vp13-positive cells, but not in vp13-negative cells (Fig 
15C). The level of PARP p85 in vp13-positive stable cells was over 60-fold higher than 










Fig 15. Activation of apoptotic pathway by vp13. A. Western blot detection of PARP-1 
cleavage in HeLa cells transfected with pCMV-H3 construct (vp13) or empty vector or 
left untransfected (mock). Cleavage of caspases 8 and 9 was also tested  in the same blot. 
Detection of β-tubulin in the same blots was conducted for normalization. B. 
Densitometric analysis of the digital image of PARP-1 blot. The PARP-1 p85 level is 
presented as relative folds in comparison with empty vector control. C. Western blot 
detection of PARP-1 in stable vp13-positive (vp13+) or -negative (vp13-) and normal 




Surprisingly, in HeLa cells that transiently express vp13, Western blot analysis 
indicated that there was no significant change in the levels of upstream initiator caspases, 
caspase-8 and -9, in vp13-expressing cells compared to cells transfected with empty 
vector or untransfected cells (Fig 15A). The caspase-8 subunit p18 or caspase-9 subunit 
p10 was not detected, indicating no cleavage or activation of these two initiator caspases.  
 
For clones of the HeLa cells that stably express vp13, we found that the levels of 
caspase 8 and 9 were similar between the stable cells and control, but the activity levels 
of caspase-3 and -7 in vp13-positive cells was 40% higher than that in vp13-negative 
cells (Fig 16A). We believed that this increased activity of caspases 3 and 7 accounted for 
the increased levels of PARP-1 cleavage observed in these cells. In order to determine if 
the increased caspase activities resulted in any alteration in cell survival and growth, we 
performed a cell viability assay. Our results from the cell growth assay did not detect any 
change in the growth rate of stable HeLa cells of both clones compared to normal HeLa 
cells (Fig 16B). These results indicate that the apoptosis pathway activation by HEV 













Fig 16. Caspase -3 and -7 activities (A) and cell viability (B) in vp13-positive stable 






5.9 MT isolation and salt extraction assay. 
  Since vp13 colocalized with MTs, we speculated that there could be a physical 
interaction between vp13 and MTs and, therefore, isolated MTs would carry vp13 protein 
along with them. HeLa cells, transiently transfected with vp13-expression plasmid, were 
homogenized in MT-stabilization buffer PEM. The cell lysate was centrifuged to separate 
MTs from free tubulin and other soluble cytoplasmic fraction. Any proteins associated 
with MTs would pellet with them during the centrifugation. SDS-PAGE analysis showed 
that vp13 was in the pellet fraction, but not in the supernatant (Fig 17A), indicating that 
vp13 physically interacted with the MTs. Acetylated α-tubulin was only detected in 
pellet, as expected. Resuspension of the MT pellet in high salt (500 mM KCl) PEMS 
buffer extracts MT-associated proteins (MAP) or MAP-like proteins as the binding of 
these proteins to the MTs is charge-dependent [see review (Maccioni & Cambiazo, 
1995)]. A new round of centrifugation with high salt PEMS buffer was carried out to 
separate MTs from MAP and MAP-like proteins. The vp13 was detected in both the 
pellet and supernatant fractions (Fig 17A). The salt extraction of vp13 from MT pellet 
indicates that vp13 behaves as MAP-like protein and the MT association appeared to 
involve an electrostatic interaction. The presence of vp13 in the pellet after the salt 
extraction indicates that vp13 also associates with subcellular organelles, which is 
consistent with the observation of punctate distribution of vp13 in addition to the linear 
array pattern under fluorescence microscopy (Fig 5). Acetylated α-tubulin was found 
only in pellet fraction. The absence of acetylated α-tubulin in the supernatant after salt 













Fig 17. Microtubule isolation and salt extraction assay. A. MT isolation with PEM buffer 
and salt extraction. The vp13 protein was detected in the pellet fraction only when the 
cells were homogenized in PEM buffer and MTs were pelleted. A portion of vp13 protein 
was shifted to supernatant fraction after extraction of MT pellet with high salt PEMS 
buffer. A portion of vp13 protein was also detected in supernatant fraction when the cells 
were homogenized in PEM buffer supplemented with ATP and GTP (AG) and MTs were 
pelleted.  Acetylated α-tubulin (Ace-tubulin) was detected only in the pellet fraction in all 
of the experiments. β-tubulin served as loading control. The supernatant fraction (S2) 
after extraction of MT pellet with PEMS buffer does not contain free tubulin. B. MT 
isolation with PEMT buffer and release of vp13 in the presence of the nucleotides. The 
vp13 protein was detected in both the pellet and supernatant fractions when the cells were 
homogenized in PEMT buffer, but in supernatant fraction only if ATP and GTP were 
included in PEMT lysis buffer. Acetylated α-tubulin was detected only in the pellet 




As the supernatant fraction after salt extraction with PEMS buffer contains motor 
proteins, MAP and MAP-like proteins, we speculated that vp13 might associate with 
motor proteins.  The cytosolic motor proteins, dynein and kinesin, can be eluted from 
MTs by nucleotides, ATP and GTP (Paschal et al., 1987). To investigate a possible 
association of vp13 with the motor proteins, MT isolation assay was done in PEM buffer 
supplemented with ATP and GTP. Western blot showed that vp13 was present in both the 
pellet and supernatant fraction (Fig 17A). Dynein was also found in the supernatant 
fraction. The presence of exogenous nucleotides reduced ability of motor proteins to 
interact with MTs, which led to shift of vp13 to supernatant.  
 
From our results, we observed vp13 in the pellet after PEM lysis or salt 
extraction. We speculated that vp13 was also present in subcellular organelles besides 
interacting with MTs and that the lysis buffer PEM was unable to lyze the organelles. 
Thus, we used the PEMT lysis buffer that included Triton X-100, to determine if the 
detergent would release vp13 from the subcellular organelles and, to see if the pellet after 
this lysis with PEMT still contains vp13 or not. Both the pellet and supernatant contained 
vp13 after lysis with PEMT buffer (Fig 17B), as expected. Addition of ATP and GTP in 
this lysis buffer shifted vp13 from pellet to supernatant (Fig 17B), indicating that the 
association of vp13 with the MTs is sensitive to the presence of nucleotides, a property 
similar to other motor proteins. Acetylated α-tubulin was found only in pellet fraction. 
These results collectively indicate that vp13 physically associates with the MTs and this 
association is nucleotide-sensitive. They also indicate that vp13 probably acts as a MAP-





5.10 Involvement of the dynein motor protein in vp13-MT interaction 
Dynein is a large protein complex and functions as a molecular motor that 
transports various cellular cargo towards the minus end of microtubules (King, 2000). 
Many viruses sequester the dynein machinery of infected cells to move along the MTs to 
reach their replication destinations (Alonso et al., 2001; Mabit et al., 2002; Ploubidou et 
al., 2000; Suomalainen et al., 1999). Furthermore, dynein binding to membranous 
organelles occurs through a second large protein complex, dynactin (King, 2000). Over 
expression of a dynactin subunit, p50/dynamitin, disrupts the dynactin complex and 
thereby dynein function (Echeverri et al., 1996).  
 
Since vp13 colocalizes with MTs and potentially associates with motor proteins, 
we examined the role of dynein motor protein in the vp13 distribution pattern. For this 
purpose, we co-transfected HeLa cells with p50/dynamitin expression plasmid and 
VenusC1-H3 and observed the cells under live fluorescent microscopy at 24 h post-
transfection. We observed that the linear array pattern of vp13 expression was abolished 
in the cells co-transfected with p50/dynamitin plasmid while no such observation was 
made in the cells transfected with vp-13 plasmid only (Fig 18, top panels). Many green 
punctates in cytoplasm were also observed. Sodium vanadate (Na3VO4) is a well-
described inhibitor of dynein activity (King, 2000). Incubation of HeLa cells with a non-
toxic concentration of 100 µM Na3VO4   for 2 h abolished the linear array pattern of vp13 




above observations with p50/dynamitin expression. Therefore, these results demonstrate 




Fig 18. Involvement of dynein in vp13-MT interaction. HeLa cells were co-transfected 
with VenusN1-H3 and p50/dynamitin constructs (left panels). Fluorescence microscopy 
was conducted 24 h after transfection.  Treatment of these cells with sodium 
orthovanadate (Na3VO4) for 2 h abolished vp13 filamentous expression pattern (bottom 




Chapter 6: Discussion and Conclusion 
 
HEV is an important virus of public health concern. HEV infections lead to 
several outbreaks in developing countries worldwide. Several aspects of HEV biology 
and pathogenesis are not clearly known due to two main reasons – one, the lack of an 
efficient cell culture system for virus propagation, and two, lack of an animal model 
system. Most of the knowledge currently available is based on studies conducted with in-
vitro synthesized replicons or individual viral proteins expressed in cells. Scientists 
around the world are involved in studying and understanding the various aspects of HEV 
molecular biology, replication and pathogenesis in spite of these limitations.  
 
HEV vp13 is a small phosphoprotein encoded by ORF3. Though it is believed to 
play a regulatory role in viral pathogenesis, its exact functions are not clearly known. 
Several researchers have found that vp13 plays a role in various cellular signaling 
pathways and that it is essential for infectivity in vivo, at least in macaques and pigs. In 
this study, we have attempted to understand and characterize the functional role of the 
vp13 protein. In particular, our work has focused on the interaction of vp13 with the cell 
structural component, mainly the microtubules and the consequences of this interaction. 
We have also studied the effect of vp13 expression on several cellular proteins that are 
involved in cell survival and growth. Our findings indicate that vp13 interacts with the 
MTs, which probably might facilitate HEV trafficking inside cells and enable efficient 




MTs are a major component of the cell structural framework. They are polarized 
filaments that have important roles in various cell functions such as cell shape 
maintenance, cell migration and intracellular transport. Several viruses use the cellular 
cytoskeletal machinery, such as actin, MTs, and their associated molecular motors, to 
traffic to the site of replication, assembly, and release (Dohner et al., 2005; Dohner & 
Sodeik, 2005; Smith & Enquist, 2002). Many viruses such as herpesvirus and 
adenoviruses traffic within infected cells specifically using the MTs (Dales & 
Chardonnet, 1973; Kristensson et al., 1986). The Tat protein of HIV, which is a powerful 
activator of viral gene expression, was also found to target MTs by interacting with 
tubulin and induce apoptosis (Chen et al., 2002). Our findings clearly indicate that vp13 
protein of HEV co-localizes with the MTs. The expression pattern of vp13 was abolished 
when transfected cells were treated with nocodazole, an agent that specifically targets and 
destabilizes the MTs, confirming that vp13 interacts with MTs. 
 
Previous reports have shown that vp13 is present in the cytoskeletal fraction and 
that in vp13 expressing cells, the protein is often seen as “speckles” in the cytoplasm 
(Tyagi et al., 2004; Zafrullah et al., 1997). A recent report shows that vp13 localizes in 
early and recycling endosomes and causes delay in the postinternalization trafficking of 
epidermal growth factor to late endosomes/lysosomes (Chandra et al., 2008). A major 
difference in our experiments was the use of Venus reporter vectors to express vp13 as a 
fusion protein.  Venus vectors contain an improved version of YFP (yellow fluorescent 
protein), named “Venus” (Nagai et al., 2002). YFP is a variant of GFP that has been used 




other related variant fluorescent proteins.  One major advantage of venus vector is 
monomeric-expression of the reporter protein, thereby avoiding over-expression and thus 
aggregation. Therefore, our results indicate a filamentous pattern of vp13 expression 
though  a speckled appearance was also visible. However, when a difference vector was 
used, we also observed aggregated proteins in big speckles in HeLa cells. Our results also 
suggest that the Venus fusion protein is a better method to be used for localization 
studies. The expression of vp13 fusion protein in COS-7 and Huh-7 cells also appeared in 
filamentous pattern, although at a lower rate, but the filament lengths were shorter than 
those observed in HeLa cells. The difference in filament length may be due to the 
difference in cell type and MT organization. Since the observation of the filamentous 
pattern was better in HeLa cells, these cells might serve as a better system to study vp13 
distribution and MT interaction.  
 
After our findings demonstrated that vp13 interacts with the MT in a specific 
manner, we determined the specific domains of vp13 that are responsible for this 
interaction. The MT interaction domain of vp13 was located in the two N-terminal 
hydrophobic domains. Both the domains were found to be essential for the interaction, 
since constructs with one of the domains did not show the filamentous expression pattern 
in cells after transient transfection. Interestingly, punctate expression pattern was 
observed in cells transfected with the construct containing the first hydrophobic domain 
of vp13, which indicates that the fusion protein could be expressed in subcellular 
organelles such as endoplasmic reticulum or Golgi. The truncation constructs containing 




indicates that the fusion proteins were soluble in cytoplasm. We also noticed that 
expression of the reporter with full-length vp13 had stronger fluorescence than that of 
truncation constructs containing the two N-terminal hydrophobic domains. It is 
speculated that the full-length vp13 might have a better interaction with MTs. The 
functional significance of vp13-MT interaction, in general, and the importance of the 
individual domains of vp13 for the MT interaction, in specific, need to be studied in 
further detail and could serve as future focus areas of this research. 
 
Acetylation and deacetylation under normal physiological conditions act as 
powerful and dynamic means of controlling MT dynamics. Cross-linking of MTs by 
cellular structures occur along their length or cap on their ends are known to cause 
acetylation and stability on MTs (Westermann & Weber, 2003). MT dynamics, a 
fundamental property of MTs, is critical for diverse cellular functions and regulated by 
many factors. Interference of the dynamics can lead to adverse consequences, including 
apoptosis (Sorger et al., 1997). Having observed that vp13 and MT interact, we continued 
to study the effect of vp13 interaction on MT stability. Therefore, we observed changes in 
MT stability, using the levels of acetylated α-tubulin as an indicator. In vp13-expressing 
cells, MT stability was enhanced, as shown by the elevation of acetylated α-tubulin. 
Thus, our results demonstrate the effect of vp13 on MT dynamics. It would be interesting 
to know if MT stability or levels of acetylated α-tubulin are also elevated in natural viral 
infections. However, our results provide a strong speculation that vp13 could serve as an 





We detected elevation in PARP-1 cleavage in cells expressing vp13. PARP-1 
cleavage is regarded as a hallmark for apoptosis. It is known that severe DNA damage 
triggers a PARP-mediated apoptosis and PARP-1 cleavage is mediated by caspase-3 
during the late phase of apoptosis (Jin & El-Deiry, 2005). Increased levels of p53 were 
demonstrated during PARP-1 cleavage following DNA damage. In the cells expressing 
vp13, elevation of p53 and caspase-3 and -7 activities were detected and may account for 
the PARP-1 cleavage. However, we did not detect any change in caspase 8 and 9 protein 
level or their cleavage in Western blotting analysis. The result indicates that elevation of 
caspase-3 and -7 was either by other unknown factors instead of caspase 8 and 9, or by 
low level of caspase-8 and -9 activities that was below detection level by Western blot. It 
has also been observed that PARP-1 activation can cause the translocation of apoptosis 
inducing factor from the mitochondria to the nucleus, leading to a caspase-independent 
apoptotic pathway (Yu et al., 2002). Whether such events also occur in vp13-expressing 
cells needs to be investigated. Though the vp13 cells have elevated PARP-1 cleavage, we 
did not observe apoptosis or change in cell viability. The reason could be that vp13 
blocks cytochrome C release (Moin et al., 2007) and vp13 has other functions that 
compromised the vp13 activation of the apoptosis pathway and protected the cells from 
death.  
 
Another important aspect of this work was to determine the effects of vp13-MT 
interaction on several cellular proteins involved in cell cycle. When we analyzed the 
levels of the tumor suppressor protein p53 and cyclin-dependent kinase inhibitor p21 




expressing cells when compared to those that do not have vp13. The vp13 interaction 
with MTs could be the stress factor that led to the p53 elevation. However, our work does 
not exclusively demonstrate the relationship of MT interaction and p53 elevation, since 
vp13 may bind to other cellular factors to activate the p53. As downstream players of 
p53, the levels of p21 and MDM2 were elevated accordingly. Because of its inhibitory 
function in cell cycle progression, p21 elevation was expected to result in slowdown of 
cell growth. However, we did not observe any significant cell growth change in cells with 
vp13 expression. It is known that p21 has dual roles in apoptosis (Pavelic et al., 2008) 
and can inhibit p53-mediated apoptosis (Sohn et al., 2006). Thus, in cells with vp13 
expression, the p21 elevation might inhibit apoptosis. However, other possible reasons 
for the absence of apoptosis in the presence of vp13 should also be considered.  
 
Molecular motors such as kinesin and dynein play important roles in cellular 
trafficking, including trafficking of viruses (Dohner et al., 2005). Cytoplasmic dynein, 
together with its activator dynactin, is a multisubunit macromolecular complex necessary 
for cargo transport. Further, dynamitin (p50) is a component of the dynein complex 
whose overexpression results in disruption of dynein-dependent transport by a dominant-
negative effect (Dohner et al., 2002). In our study, dynein motor function was found to be 
critical for the vp13 colocalization with MTs since over expression of p50/dynamitin 
abolished the vp13 expression pattern. In addition, treatment of cells with sodium 
vanadate, a well-described inhibitor of dynein activity, altered the filamentous pattern of 




and the binding lead to the colocalization with MTs. However, we do not have direct 
evidence to demonstrate interaction between vp13 and dynein complex. 
  
           To further address the interaction of vp13 with MT, we resorted to a MT isolation 
assay that used detergent and salt treatments. Our results indicated that vp13 interaction 
with MTs occurs through the dynein motor protein complex since vp13 was found in MT 
pellet and extracted from the pellet with high salt buffer. This result was consistent with 
the observation of fluorescence microscopy that showed the vp13 colocalization with 
MTs. In this assay, the vp13 transiently transfected cells were used for MT isolation. The 
presence of vp13 in MT pellet indicated direct interaction of vp13 with MTs. Salt 
extraction of the MT pellet removed vp13, which indicated that vp13 behaved like an 
MAP or MAP-like protein, since high salt buffer did not favor their binding to MTs. The 
presence of vp13 in the supernatant fraction in the presence of ATP and GTP showed that 
vp13 may associate with motor proteins complex. It has been proposed that HEV ORF3 
protein may have a role in virion release (Takahashi et al., 2008). Furthermore, recent 
studies have shown that ORF3 protein was detected on the surface of virions released 
from infected cells, but not those from feces (Takahashi et al., 2008). Our findings that 
vp13 protein interacted with motor proteins indicated that it may utilize the motor protein 
for virion trafficking. We speculate that vp13 interaction with MTs is due to vp13 
binding with other MAP-like proteins because ionic interaction was responsible for the 
interaction and the two N-terminal domains of vp13 were needed for the colocalization 




immunoprecipitation with tubulin antibody failed to precipitate vp13 (Zafrullah et al., 
1997).  
 
In conclusion, our data demonstrate that vp13 interacts with MTs and interferes 
with their dynamics, which could create a conducive intracellular-environment for the 
establishment of successful HEV infection. The vp13 association with MTs led to 
modulation of MT dynamics by elevating their stability. The association also led to 
activation of apoptosis pathway, shown by elevation of PARP-1 cleavage and caspase-3 
and -7 activities. However, no adverse on cell growth was detected, which might be 
vp13’s other functions aborting the apoptosis induction. Furthermore, we have identified 
the MT-binding regions of vp13 in both the N-terminal hydrophobic domains. Our results 
also showed that vp13 expression in HeLa cells increased the levels of cellular proteins 
p53 and p21. An important finding in this study was the involvement of dynein in vp13-
MT interaction and that vp13 behaves as a MAP-like protein. These results advance our 
understanding of HEV vp13 function. Further studies are needed to elucidate the 
mechanism and the biological effects of the MT modulation. Studying the vp13 
interaction with the MTs and the role of molecular motors dynein and kinesin in the 
interaction will assist our understanding of HEV pathogenesis. Moreover, delineating the 
strategy for viral protein binding to the MTs provides clue to the development of novel 
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